Journal Article

Operative treatment of cystic prolactinomas: a retrospective study

Yang, Lixuan, Yang, Yibing, Yang, Jia, Su, Weijie, Tang, Hongxing, Li, Xixi, He, Kejun, Xu, Jiakun

2023

Overview

Background The optimal therapeutic approach for cystic prolactinomas remains unclear. This study aimed to evaluate the remission rates of prolactinoma patients after surgical treatment and the risk factors affecting postoperative remission in cystic prolactinoma patients. Methods The clinical data were retrospectively compiled from 141 patients with prolactinomas (including 41 cases of cystic prolactinomas, 21 cases of solid microprolactinomas and 79 cases of solid macroprolactinomas) who underwent transsphenoidal surgery (TSS) between April 2013 and October 2021 at the First Affiliated Hospital of Sun Yat-sen University. Results Early postoperative remission was achieved in 65.83% (n = 27/41) of cystic prolactinomas, 80.95% (n = 17/21) of solid microprolactinomas and 40.51% (n = 32/79) of solid macroprolactinomas. The mean length of follow up in all patients was 43.95 ± 2.33 months (range: 6-105 months). The follow-up remission rates were 58.54%, 71.43% and 44.30% in cystic, solid micro- and solid macroprolactinomas, respectively. For cystic prolactinomas, the early postoperative remission rates in the patients with preoperative dopamine agonists (DA) treatment were significantly higher than those without preoperative DA treatment ( p =  0.033), but the difference in the follow-up remission rates between these two groups was not significant ( p =  0.209). Multivariate stepwise logistic regression analysis indicated that tumor size and preoperative prolactin (PRL) levels < 200 ng/ml were independent predictors for early postoperative remission in cystic prolactinomas. Conclusion For cystic prolactinomas, tumor size and preoperative PRL levels were independent predictors of early postoperative remission. Preoperative DA therapy combined with TSS may be more beneficial to cystic prolactinoma patients.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Adenoma / Agonists / Cabergoline / Cancer / Cystic prolactinomas / Cysts / Diabetes / Dopamine / Dopamine agonists / Dopamine Agonists - therapeutic use / Endocrinology / Humans / Magnetic resonance imaging / Medicine / Medicine & Public Health / Metabolic Diseases / Patients / Pituitary / Pituitary gland / Pituitary Neoplasms - drug therapy / Pituitary Neoplasms - surgery / Preferences / Prolactin / Prolactinoma - drug therapy / Prolactinoma - surgery / Prolactinomas / Remission / Remission (Medicine) / Retrospective Studies / Risk factors / rology / Surgery / Surgical remission / Transsphenoidal surgery / Treatment Outcome / Tumors